CARB-X funds TAXIS PHARMACEUTICALS to accelerate development of innovative efflux pump inhibitors (EPIS), a new drug class that would impair bacteria’s ability to fight antibiotics

  09 January 2020

CARB-X is awarding TAXIS Pharmaceuticals of Monmouth Junction, New Jersey, USA, up to US$3.2 million in non-dilutive funding to develop efflux pump inhibitors (EPI), a new drug class designed to destroy a major mechanism of multi-drug-resistant Pseudomonas aeruginosa bacteria. TAXIS is eligible for an additional funding of up to $11.4 million if the project achieves certain milestones. TAXIS’ EPIs are designed to disable the bacteria’s efflux pumps, which act like bilge pumps to flush out antibiotics from the bacterial cell in order to safeguard the superbug from the effects of antibiotics.

Further reading: CARB-X
Author(s): Jennifer Robinson
Smart Innovations  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University


Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!